Lin BioScience Company Description

Lin BioScience, Inc., a drug development company, develops therapies for oncology, ophthalmology, and metabolic diseases.

Its product pipeline includes LBS-008, an oral therapy for dry age-related macular degeneration (Dry AMD)and stargardt diseases (STGD1), which is under Phase 3 clinical trial to evaluate safety and efficacy in adolescent STGD1 and under phase 2 or phase 3 clinical trial to evaluate safety and efficacy in Dry AMD; LBS-007, a natural non-ATP CDC7 inhibitor for the treatment of cancers; LBS-002, an anti-tubulin to treat primary and metastatic brain tumors; and LBS-009, an oral therapy for the treatment of non-alcoholic fatty liver disease and type 2 diabetes.

The company is headquartered in Taipei, Taiwan.

Lin BioScience, Inc.

Country	Taiwan
Industry	Biotechnology
Sector	Healthcare
CEO	Zhengqi Wang

Contact Details

Address: No. 68, Zhongxiao East Road Taipei, 110 Taiwan
Phone	886 2 8780 5008
Website	linbioscience.com

Stock Details

Ticker Symbol	6696
Exchange	Taipei Exchange
Fiscal Year	January - December
Reporting Currency	TWD
ISIN Number	TW0006696008
SIC Code	2836

Key Executives

Name	Position
Dr. Zhengqi Wang M.B.A., Ph.D.	President, CSO and Director
Serena Chen	Chief Financial Officer